TNFRSF17 and neoplasm: In contrast, no BCMA antigen loss was observed in tumors treated with Allo15BCAR-NKT cells (Fig. 5b,c and Supplementary Fig. 11), which could be attributed to the multiple tumor-targeting mechanisms employed by Allo15BCAR-NKT cells (Fig. 2).